Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 2
80
about 3.1 years
18+
5 sites in CA, FL, NJ +2
What this study is about
This trial is testing the safety and effectiveness of a treatment called Orca-T for people with acute myeloid leukemia or myelodysplastic syndromes who are undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation. Orca-T is an immunotherapy biologic made from stem cells, regulatory T cells, and conventional T cells derived from a specific donor.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Orca-T
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: RIC Cohort: GVHD-free and relapse-free survival (GRFS)
Secondary: GVHD-free and relapse-free survival (GRFS), Incidence of chronic GVHD, Non-relapse mortality, Overall survival, Relapse-free survival
Oncology